Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review
Urologia Internationalis · 2023 · 107 (3) · 321-326
DOI: 10.1159/000528447 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Urologia Internationalis, online erschienen am 02.02.2023. Verfasst von Yukari Bando und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Kidney Failure, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Combination therapies of an immune checkpoint inhibitor and a molecular targeted agent are widely accepted as an appropriate initial systemic therapy for metastatic renal cell carcinoma (RCC), but there is little published evidence regarding the efficacy of this approach in patients with end-stage renal disease (ESRD). Here, we report three patients who were undergoing hemodialysis for ESRD whose metastatic RCC was successfully treated using avelumab plus axitinib. The patients were a 67-year-old man with swollen lymph nodes, a 65-year-old man with pleural dissemination, and a 71-year-old man with lung nodules and an infra-diaphragmatic nodule. They were administered a combination of avelumab plus axitinib as their initial systemic therapy following definitive surgical therapy. The best response of three patients was graded as partial response. No severe adverse events were identified. This is the first report of the use of combination therapy consisting of avelumab plus axitinib in patients with ESRD undergoing hemodialysis. We found that this combination was useful in such patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Zitieren
APA
Bando, Y., Furukawa, J., Hara, T., Okamura, Y., Terakawa, T., Nakano, Y., & Fujisawa, M. (2023). Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review. Urologia Internationalis, 107(3), 321-326. https://doi.org/10.1159/000528447
Vancouver
Bando Y, Furukawa J, Hara T, Okamura Y, Terakawa T, Nakano Y, et al. Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review. Urologia Internationalis. 2023;107(3):321-326. doi:10.1159/000528447
BibTeX
@article{Bando2023,
author = {Bando, Yukari and Furukawa, Junya and Hara, Takuto and Okamura, Yasuyoshi and Terakawa, Tomoaki and Nakano, Yuzo and Fujisawa, Masato},
title = {Avelumab plus Axitinib for the Treatment of Patients with End-Stage Renal Disease Undergoing Dialysis: A Retrospective Case Series and Literature Review},
journal = {Urologia Internationalis},
year = {2023},
volume = {107},
number = {3},
pages = {321--326},
doi = {10.1159/000528447}
}
EUVIMED